## APC-Labeled Monoclonal Anti-FMC63 Antibody, Mouse IgG1 (Y45) (Site-specific conjugation)

Catalog # FM3-AY54P1



#### Source

APC-Labeled Monoclonal Anti-FMC63 Antibody, Mouse IgG1 (Y45) (FM3-AY54P1) is produced via site-specific conjugation of APC to Monoclonal Anti-FMC63 scFv Antibody, Mouse IgG1 under optimal conditions with a proprietary technology.

#### **Isotype**

Mouse IgG1/kappa

## **Specificity**

Specifically recognizes the antigen-recognition domain of FMC63 derived CARs.

## Conjugate

APC

Excitation Wavelength: 640 nm

Emission Wavelength: 661 nm

#### **Application**

Flow Cytometry (Evaluation of Anti-CD19 (FMC63 scFv) CAR Expression). Please note that this product is NOT compatible to streptavidin detection system.

#### **Endotoxin**

Less than 1.0 EU per µg by the LAL method.

#### **Formulation**

Lyophilized from  $0.22~\mu m$  filtered solution in PBS, 0.5% BSA, pH7.4 with trehalose as protectant.

Contact us for customized product form or formulation.

#### Reconstitution

Please see Certificate of Analysis for specific instructions.

For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

#### Storage


For long term storage, the product should be stored at lyophilized state at -20°C or lower.

Please avoid repeated freeze-thaw cycles.

This product is stable after storage at:

- -20°C to -70°C for 12 months in lyophilized state;
- -70°C for 12 months under sterile conditions after reconstitution.

### **Bioactivity-FACS**



5e5 of anti-CD19 CAR-293 cells were stained with 100  $\mu$ L of 1:50 dilution (2  $\mu$ L stock solution in 100  $\mu$ L FACS buffer) of APC-Labeled Monoclonal Anti-FMC63 Antibody, Mouse IgG1 (Y45) (Cat. No. FM3-AY54P1) and isotype control antibody respectively. APC signal was used to evaluate the binding activity (QC tested).



# APC-Labeled Monoclonal Anti-FMC63 Antibody, Mouse IgG1 (Y45) (Site-specific conjugation)

Catalog # FM3-AY54P1



## **Background**

FMC63 is an IgG2a mouse monoclonal antibody specific for CD19, which is a target for the immunotherapy of B lineage leukaemias and lymphomas. FMC63 scFv is the most commonly used ectodomain component of CD19-specific CARs. So far, most of reported CART19 trials contain the anti-CD19 scFv derived from FMC63, including the two FDA-approved CARs Kymriah and Yescarta.

**Clinical and Translational Updates** 

